These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12065187)

  • 1. Decisions facing the cystic fibrosis clinician at first isolation of Pseudomonas aeruginosa.
    Bush A
    Paediatr Respir Rev; 2002 Mar; 3(1):82-8. PubMed ID: 12065187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The success of the different eradication therapy regimens for Pseudomonas aeruginosa in cystic fibrosis.
    Emiralioglu N; Yalcin E; Meral A; Sener B; Dogru D; Ozcelik U; Kiper N
    J Clin Pharm Ther; 2016 Aug; 41(4):419-23. PubMed ID: 27311742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vitro Antibiotic Susceptibility of Initial Pseudomonas aeruginosa Isolates From United States Cystic Fibrosis Patients.
    VanDevanter DR; Van Dalfsen JM; Burns JL; Mayer-Hamblett N
    J Pediatric Infect Dis Soc; 2015 Jun; 4(2):151-4. PubMed ID: 26407415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of serology and spirometry and the combination of both to complement microbiological isolation for earlier detection of Pseudomonas aeruginosa infection in children with cystic fibrosis.
    Kotnik Pirš A; Krivec U; Simčič S; Seme K
    BMC Pulm Med; 2016 Nov; 16(1):161. PubMed ID: 27884144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
    Hansen CR; Pressler T; Høiby N
    J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The social network of cystic fibrosis centre care and shared Pseudomonas aeruginosa strain infection: a cross-sectional analysis.
    Kidd TJ; Soares Magalhães RJ; Paynter S; Bell SC;
    Lancet Respir Med; 2015 Aug; 3(8):640-50. PubMed ID: 26208994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Approach to Pseudomonas aeruginosa in Cystic Fibrosis.
    Talwalkar JS; Murray TS
    Clin Chest Med; 2016 Mar; 37(1):69-81. PubMed ID: 26857769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis.
    Høiby N
    Paediatr Drugs; 2000; 2(6):451-63. PubMed ID: 11127845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in strategies for optimal antibacterial therapy in cystic fibrosis.
    Ratjen F
    Int J Antimicrob Agents; 2001 Feb; 17(2):93-6. PubMed ID: 11165111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
    Ciofu O
    APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The approach to Pseudomonas aeruginosa in cystic fibrosis.
    Bendiak GN; Ratjen F
    Semin Respir Crit Care Med; 2009 Oct; 30(5):587-95. PubMed ID: 19760546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic perturbation of mixed-strain Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Tai AS; Sherrard LJ; Kidd TJ; Ramsay KA; Buckley C; Syrmis M; Grimwood K; Bell SC; Whiley DM
    BMC Pulm Med; 2017 Nov; 17(1):138. PubMed ID: 29096618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rhesus θ-defensin-1 (RTD-1) exhibits in vitro and in vivo activity against cystic fibrosis strains of Pseudomonas aeruginosa.
    Beringer PM; Bensman TJ; Ho H; Agnello M; Denovel N; Nguyen A; Wong-Beringer A; She R; Tran DQ; Moskowitz SM; Selsted ME
    J Antimicrob Chemother; 2016 Jan; 71(1):181-8. PubMed ID: 26433781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infection with transmissible strains of Pseudomonas aeruginosa and clinical outcomes in adults with cystic fibrosis.
    Aaron SD; Vandemheen KL; Ramotar K; Giesbrecht-Lewis T; Tullis E; Freitag A; Paterson N; Jackson M; Lougheed MD; Dowson C; Kumar V; Ferris W; Chan F; Doucette S; Fergusson D
    JAMA; 2010 Nov; 304(19):2145-53. PubMed ID: 21081727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of Pseudomonas aeruginosa location in the lungs of patients with cystic fibrosis.
    Moore JE; Mastoridis P
    J Clin Pharm Ther; 2017 Jun; 42(3):259-267. PubMed ID: 28374433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of Pseudomonas aeruginosa infection and the role of contamination of the environment in a cystic fibrosis clinic.
    Zimakoff J; Høiby N; Rosendal K; Guilbert JP
    J Hosp Infect; 1983 Mar; 4(1):31-40. PubMed ID: 6190882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung infection with alginate-producing, mucoid Pseudomonas aeruginosa in cystic fibrosis.
    Pedersen SS
    APMIS Suppl; 1992; 28():1-79. PubMed ID: 1449848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis.
    Pedersen SS; Høiby N; Espersen F; Koch C
    Thorax; 1992 Jan; 47(1):6-13. PubMed ID: 1539148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucoid Pseudomonas aeruginosa. A sign of cystic fibrosis in young adults with chronic pulmonary disease?
    Reynolds HY; Di Sant'Agnese PA; Zierdt CH
    JAMA; 1976 Nov; 236(19):2190-2. PubMed ID: 824466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating the variation in the incidence of new Pseudomonas aeruginosa infection between paediatric cystic fibrosis centres.
    Gilchrist FJ; Jones AM; Smyth AR; Southern KW; Webb AK; Lenney W
    J Cyst Fibros; 2017 Sep; 16(5):e14-e16. PubMed ID: 28690130
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.